181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 181,294 shares of the company's stock, valued at approximately $5,461,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Public Employees Retirement System of Ohio grew its stake in Teva Pharmaceutical Industries by 9.1% during the first quarter. Public Employees Retirement System of Ohio now owns 84,068 shares of the company's stock worth $2,532,000 after buying an additional 7,000 shares during the period. Compound Planning Inc. raised its stake in shares of Teva Pharmaceutical Industries by 10.4% in the 1st quarter. Compound Planning Inc. now owns 11,418 shares of the company's stock valued at $344,000 after acquiring an additional 1,075 shares during the period. Sei Investments Co. lifted its holdings in shares of Teva Pharmaceutical Industries by 22.5% during the 1st quarter. Sei Investments Co. now owns 1,182,751 shares of the company's stock valued at $35,624,000 after acquiring an additional 217,487 shares in the last quarter. Lido Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 10.9% during the 1st quarter. Lido Advisors LLC now owns 20,197 shares of the company's stock valued at $608,000 after acquiring an additional 1,990 shares in the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Teva Pharmaceutical Industries by 44.3% during the 1st quarter. Cetera Investment Advisers now owns 87,216 shares of the company's stock valued at $2,627,000 after acquiring an additional 26,789 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Amir Weiss sold 10,679 shares of the business's stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares in the company, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 444,673 shares of company stock valued at $15,582,369 in the last three months. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $34.55 on Thursday. The company has a fifty day simple moving average of $33.19 and a 200 day simple moving average of $32.69. The firm has a market cap of $39.73 billion, a price-to-earnings ratio of 25.98, a PEG ratio of 3.35 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The firm had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Truist Financial increased their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, April 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Friday, July 17th. UBS Group upped their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, April 30th. Bank of America increased their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 9th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative medicines delivered strong growth. Teva said its key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in second-quarter revenue. The company raised its 2026 outlook for all three key brands, supporting its strategy of shifting beyond lower-margin generics. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum was particularly encouraging. U.S. sales of the long-acting schizophrenia treatment reached a record $77 million, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million previously. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Revenue guidance exceeded expectations. Teva forecast 2026 revenue of $16.5 billion-$16.9 billion, broadly aligned with the $16.7 billion consensus but described by investors as better than expected. Piper Sandler also raised its price target to $44 from $42 and maintained an Overweight rating. Teva Stock Rises After Earnings
• Neutral Sentiment: Options activity reflected increased bullish interest. Traders purchased 23,688 call options, approximately 136% above typical daily call volume. This may amplify short-term momentum, but it is not a fundamental indicator of business performance.
• Negative Sentiment: Quarterly profitability fell short. Teva reported second-quarter EPS of $0.02, below the $0.08 consensus and down from $0.66 a year earlier. Revenue of $4.14 billion exceeded estimates of $4.02 billion but declined roughly 1% year over year, primarily because of weaker generics revenue. Teva Quarterly Earnings Report
• Negative Sentiment: EPS guidance was below Wall Street expectations. Teva projected 2026 EPS of $1.91-$2.11 versus the $2.17 consensus, creating a counterweight to the improved revenue outlook and strong branded-drug performance.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.